Bioceres (BIOX) Q4 2026 Earnings Call Transcript
Bioceres (BIOX) reported a challenging fiscal year 2026 with an 18% revenue decline to $238M, driven by seed business reconfiguration and lower crop protection performance. Quarterly revenue was $55.9M, with crop nutrition revenue growing 36%. Adjusted EBITDA improved to $600K from a $9.6M loss, aided by a 19% reduction in SG&A expenses. The company faces litigation and debt restructuring challenges, with total financial debt at $225.9M. Management targets a 40% gross margin for fiscal 2027 and
How this was made
The 30-second read
Why it matters
The earnings release provides fresh guidance on profitability and debt, offering traders new data to reassess valuation.
Market read
Earnings data introduces material new information for BIOX investors, with mixed signals on growth and financial health.
What to watch
Potential upside from microbeaded fertilizer growth and upcoming Brazil market expansion.
Background
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) reported its fiscal Q4 2026 and full‑year results, detailing revenue trends, margin changes, and debt restructuring.
Ticker impact
Q4 2026 earnings release shows revenue down 18% YoY, adjusted EBITDA turning positive, and debt restructuring in Argentina.
Potential modest upside if investors focus on EBITDA improvement; downside if revenue decline dominates.
Positive EBITDA swing offsets revenue weakness, but elevated debt and litigation risk limit upside.
Market effects
Highlights challenges in agri‑tech seed segment and potential shift toward crop‑nutrition products.
Debt restructuring in Argentina may affect other Latin American agri‑companies.
Limited, confined to niche biotech/agri‑tech investors.
Counterpoint
Despite revenue decline, the EBITDA turnaround and debt repricing could signal a turnaround opportunity.
Key entities
- companyBioceres Crop Solutions Corp.
Agri‑technology firm listed on NASDAQ under BIOX.
